Intellia tumbles after US FDA halts key heart disease trials following patient death

INTELLIA THERAPEUTICS

07/11/2025 15:33

Updates

** Shares of gene therapy developer Intellia Therapeutics NTLA.O fall 23% to $9.49, their lowest in five months

** Co said late on Thursday said that U.S. FDA has paused its two main late-stage trials for a gene-editing treatment after a patient died from severe liver complications

** The trials were studying the treatment nexiguran ziclumeran in debilitating heart diseases ATTR amyloidosis with cardiomyopathy and hereditary ATTR amyloidosis with polyneuropathy

** Co consulting experts and regulators on next steps - NTLA

** Despite the setback, NTLA said it remains confident in the potential of nexiguran ziclumeran, to help patients with amyloidosis, a rare disease caused by protein buildup

** NTLA to present early-stage heart disease data for nex-z, on November 10, co says

** Including session's move, stock down ~15% YTD

 (Reporting by Sahil Pandey in Bengaluru)

 ((Sahil.Pandey@thomsonreuters.com))